🔗 Visit the ClinicalTrials.gov page for NCT00532389
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. | Immunol Cell Biol | 2011 | 1.05 |
| 2 | Targeting the UPS as therapy in multiple myeloma. | BMC Biochem | 2008 | 1.05 |
| 3 | Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. | J Biomed Biotechnol | 2010 | 1.03 |
| 4 | Targeting Histone Deacetylases in Diseases: Where Are We? | Antioxid Redox Signal | 2014 | 0.88 |
| 5 | Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. | Eur J Clin Pharmacol | 2015 | 0.76 |
| 6 | Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. | Onco Targets Ther | 2016 | 0.75 |